Carotid Intraplaque Neovascularization Combined With Stress Echo
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Carotid Contrast Enhanced Ultrasound.
- Who it may be relevant to
- Registry conditions: Atherosclerosis, Cardiovascular Diseases, Acute Coronary Syndrome, Ischemic Heart Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Combining Intraplaque Neovascularization With Risk Stratification by Carotid Stress ECHO
Overview
The root cause of heart attacks and strokes is atherosclerosis, the hardening and thickening of blood vessels due to the presence of "plaque" which is a build-up of fat and cholesterol in the walls of vessels. To diagnose heart disease, patients receive a stress test to find out if they require surgery. Up to 52% of patients receiving an angiogram (surgery) to look at plaque blockages in the heart are found to be normal (no blockage). Patients who are suspected of having heart disease often undergo a stress test, which helps cardiologists decide if the patient has heart disease, but stress tests can give false results. In Ontario alone, 90% are stress tests are found to be normal and patients are sent home with little follow-up. Of these 3-5% (\~4,000 patients/year) will have a major cardiovascular event (heart attack, surgery, or death) within 3 years. We need to improve the stress test accuracy to reduce cardiac outcome. We now know that it is not just the total amount of plaque that leads to heart attacks and strokes, but the composition of the plaque that can lead to breakage causing a heart attack. Plaques are soft and fragile, and typically contain fat and small leaky blood vessels within their cores. If we are able to identify patients that have leaky plaques using ultrasound, we may be able to improve the accuracy of stress testing. We propose a study looking at the combination of stress testing (assessing heart function) and neck ultrasound (assessing plaque composition), to identify patients at risk for cardiovascular events (heart attacks and death). We will enrol patients from 6 sites across Canada and follow-them for cardiac outcome for 3 years.
Detailed description
Primary Aim: To determine if carotid intraplaque neovascularization score (IPN) combined with stress echo (SE) \[IPN+SE\] enhances prediction of 3-year major adverse cardiovascular events (MACE) compared to SE alone.
Objectives: 1) The % change in test sensitivity of IPN+SE for predicting 3-year MACE compared with SE alone. 2) The Net Reclassification Improvement (NRI) for MACE will be determined (patients "missed" by the SE, but captured as high risk for MACE by IPN).
Interventions
- Other Carotid Contrast Enhanced Ultrasound
Carotid Contrast-Enhanced Ultrasound (CEUS), a diagnostic ultrasound enhancing agent that opacifies the blood to delineate the vessel walls.
Primary outcome measures
- Our primary outcomes will be the improvement in sensitivity and negative predictive value (NPV). [Time frame: This is a 5-year study. The outcome follow up for mace will be 3-years from the index date (SE).]
Eligibility criteria
Inclusion criteria
- Men and women >18 years;
- Referred for a clinically indicated SE for assessment of ischemia and risk stratification;
- Able and willing to give informed consent.
Exclusion criteria
- Emergency procedure, or active acute coronary syndrome (active chest pain, ischemic electrocardiogram changes, or cardiac enzyme elevation);
- Referral for viability, pulmonary hypertension, or valve assessment;
- Referral outside of the normal working hours;
- History of significant CAD: percutaneous coronary intervention (PCI), coronary artery bypass graft (GABG), or coronary angioplasty;
- History of stroke or myocardial infarction (MI);
- Known or documented hypersensitivity or allergy to perflutren (DEFINITY® contrast agent);
- Known or documented allergy to Polyethylene Glycol (Peg) a component of DEFINITY®;
- History of carotid surgery (endarterectomy or stenting);
- Any serious medical condition or complication from the stress test that according to the investigator could interfere with the carotid scan or optimal care;
- Currently pregnant or breastfeeding;
- Previous enrolment into the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Canada · 6 centers
- University of Calgary — Calgary
- University of Alberta — Edmonton
- Dalhousie University — Halifax
- The Kingston Heart Clinic — Kingston
- Queen's University, Cardiovascular Imaging Network at Queen's (CINQ) — Kingston
- Unity Health Toronto — Toronto
Identifiers
NCT: NCT05416385 · DMED-2469-21-6032717 · CG#21007 · 452696